AEON Biopharma cuts warrant exercise price to $0.20, expects $6.2 million in proceeds
On November 2, 2026, AEON Biopharma amended its two-year milestone warrants to reduce their exercise price from about $0.32 to $0.20 per share, with holders of at least 67% of the underlying shares agreeing. Certain holders have agreed to exercise at the lower price, and the company expects about $6.2 million in gross proceeds. The amendment applies to all outstanding warrants, which expire on November 16, 2026, after the FDA's September 30 feedback triggered accelerated expiration.
Key points
- Exercise price cut from $0.3221 to $0.20 per common share, effective November 2, 2026
- Company expects approximately $6.2 million in gross proceeds from warrant exercises
- Amendment applies to all outstanding Two-Year Warrants; share count and expiration date unchanged
- Warrants expire November 16, 2026; 71,517,020 common shares were outstanding as of October 30, 2026
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 03, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.